Antibiotic resistance in community-acquired urinary tract infections: Prevalence and risk factors

Medical Science Monitor

Volumn 16, Issue 5, 2010, Pages

  Kurtaran, Behice ^a   Candevir, Aslihan ^a   Tasova, Yesim ^a   Kibar, Filiz ^a   Inal, Ayse Seza ^a   Komur, Suheyla ^a   Aksu, Hasan Salih Zeki ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

Author keywords

Antibiotic resistance; Community; Urinary tract infection

Indexed keywords

AMIKACIN; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; COMMUNITY ACQUIRED URINARY TRACT INFECTION; ENTEROCOCCUS; ENZYME SYNTHESIS; ESCHERICHIA COLI; FEMALE; HUMAN; INFECTION RISK; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; PROSPECTIVE STUDY; PROTEUS MIRABILIS; URINARY TRACT INFECTION; COMMUNICABLE DISEASE; MICROBIOLOGY; MIDDLE AGED; TURKEY (REPUBLIC);

ADULT; AGED; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, MICROBIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; TURKEY; URINARY TRACT INFECTIONS;

EID: 77954283465     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev, 2005; 18: 657-86
2. Doi Y, Adams J, O'Keefe A et al: Community-acquired extended-spectrum b-lactamase producers, United States. EID Journal Home, 2007; 13(7)
3. Gupta K, Hooton TM, Stamm WE: Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections. Ann Intern Med, 2001;135: 41-50
4. Livermore DM, Canton R, Gniadkowski M et al: CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother, 2007; 59(2): 165-74
5. Rodríguez-Baño J, Navarro MD, Romero L et al: Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamaseproducing Escherichia coli in nonhospitalized patients. J Clin Microbiol, 2004; 42(3): 1089-94
6. Sobel JD, Kaye D: Urinary tract infection. In: Principles and Practice of Infectious Diseases. Mandell GL, Douglas JE, Bennett R (eds.) 6th edition
7. Hooton TM, Stamm WE: Diagnosis and treatment of uncomplicated urinary tract infection. Infect Dis Clin North Am, 1997; 11: 551-81
8. Ronald AR, Harding GK: Complicated urinary tract infections. Infect Dis Clin North Am, 1997; 11: 583-92
9. Clinical and Laboratory Standards Institute (CLSI). Performance standard for antimicrobial susceptibility testing. Fifteenth informational supplement. Document M100-S15 (2005) CLSI, Wayne, PA, USA
10. Uzunovic-Kamberovic S, Saric D, Sestic S: Community-acquired urinary tract infections by extended-spectrum beta-lactamase-producing Enterobacteriaceae in Zenica-Doboj Canton, Bosnia and Herzegovina. Medicinski Glasnik, 2006; 3(2): 46-52
11. Pitout JD, Gregson DB, Church DL et al: Community-wide outbreaks of clonally related CTX-M-14 beta-lactamase - producing Escherichia coli strains in the Calgary health region. J Clin Microbiol, 2005; 43: 2844-49
12. Sorlózano A, Gutiérrez J, Palanca M et al: High incidence of extendedspectrum b-lactamases among outpatient clinical isolates of Escherichia coli: A phenotypic assessment of NCCLS guidelines and a commercial method. Diagn Microbiol Infect Dis, 2004: 131-34
13. Arpin C, Dubois V, Coulange L et al: Extended-spectrum b lactamaseproducing Enterobacteriaceae in community and private health care centers. Antimicrob Agents Chemother, 2003; 47: 3506-14
14. Warren JW, Abrutyn E, Hebel JR et al: Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis, 1999; 29(4): 745-58
15. Zhanel GG, Karlowsky JA, Harding GKM et al: The Canadian Urinary Isolate Study Group, and D. J. Hoban. A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxazole, ampicillin, mecillinam, nitrofurantoin, and ciprofloxacin. Antimicrob Agents Chemother, 2000; 44: 1089-92
16. Zervos MJ, Hershberger E, Nicolau DP et al: Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis, 2003; 37(12): 1643-48
17. Diekema, DJ, BootsMiller BJ, Vaugh TE et al: Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin Infect Dis, 2004; 38: 78-85
18. Goettsch W, van Pelt W, Nagelkerke N et al: Increasing resistance to fluoroquinolones in Escherichia coli from urinary tract infections in the netherlands. J Antimicrob Chemother, 2000; 46(2): 223-28
19. Karlowsky JA, Kelly LJ, Thornsberry C et al: Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother, 2002; 46(8): 2540-45
20. Karlowsky JA, Hoban DJ, deCorby MR et al: Fluoroquinolone-Resistant Urinary Isolates of Escherichia coli from Outpatients Are Frequently Multidrug Resistant: Results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance Study. Chemother Antimicrobial Agents and Chemotherapy, June, 2006: 2251-54
21. Bolon MK, Wright SB, Gold HS, Carmeli Y: The magnitude of the association between fluoroquinolone use and quinolone-resistant Escherichia coli and Klebsiella pneumoniae may be lower than previously reported. Antimicrob Agents Chemother, 2004; 48: 1934-40
22. Ena J, Amador C, Martinez C et al: Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli. J Urol, 1995; 153(1): 117-20
23. Arslan H, Azap ÖK, Ergönü O, Timurkaynak F and Urinary Tract Infection Study Group: Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. Journal of Antimicrobial Chemotherapy, 2005; 56: 914-18